JPET #216382

Clinically relevant doses of candesartan inhibit growth of prostate tumor xenografts *in vivo* through modulation of tumor angiogenesis

Ahmed Alhusban, Ahmad Al-Azayzih, Anna Goc, Fei Gao, Susan C. Fagan, and Payaningal R. Somanath

Journal of Pharmacology and Experimental Therapeutics

S1



Supplemental Figure 1: Candesartan has no effect on long-term prostate cancer cell proliferation *in vitro*. Bar graph showing the effect of 72 hour treatment with clinical doses of candesartan on PC3 cell proliferation determined by BrdU incorporation assay. Data presented as Mean + SD.

S2



Supplemental Figure 2: Candesartan inhibits VEGF expression in prostate cancer DU145 cells in vitro in a dose-dependent manner. (A) Representative Western blot picture of DU145 cell lysates (below) and bar graph (above) showing dose-dependent reduction in VEGF expression with candesartan treatment as compared to vehicle treated controls. (B and C) Representative Western blot picture (bottom) of DU145 cell lysates and bar graph (above) showing no changes in the expression of AT1 and AT2 receptors upon treatment with clinical doses of candesartan, respectively. Data presented as Mean + SD.